Pain Research and TreatmentVolume 2013 (2013), Article ID 960270, 2 pageshttp://dx.doi.org/10.1155/2013/960270

Erratum

Erratum to “Fibromyalgia Syndrome: Etiology, Pathogenesis, Diagnosis, and Treatment”

Enrico Bellato,¹ Eleonora Marini,¹ Filippo Castoldi,¹ Nicola Barbasetti,¹ Lorenzo Mattei,¹ Davide Edoardo Bonasia,² and Davide Blonna¹

¹Department of Orthopedics and Traumatology, Mauriziano Umberto I Hospital, University of Turin Medical School, Largo Turati 62, 10128 Turin, Italy²Department of Orthopedics and Traumatology, CTO-Maria Adelaide Hospital, University of Turin Medical School, Via Zuretti 29, 10126 Turin, Italy

Received 9 January 2013; Accepted 9 January 2013

Copyright © 2013 Enrico Bellato et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In this paper which appeared in Pain Research and Treatment (Volume 2012, Article ID 426130) the affiliations have been switched. The affiliations should appear as shown above.

Moreover in Table 3 on page 10 the NNTs of Milnacipran and of Duloxetine have been switched. The NNTs should appear as follows: Milnacipran NNT 19 (95% CI 7.4, 20.5) and Duloxetine NNT 7.2 (95% CI 5.2, 11.4). The corrected full Table 3 is shown later.

Table 3: Comparison between American Pain Society (APS) and Association of the Scientific Medical Societies in Germany (AWMF) with European League Against Rheumatism (EULAR).

Nonpharmacologic treatment
Medications

American Pain Society (APS) and Association of the Scientific Medical Societies in Germany (AWMF)
Strong evidence:
Strong evidence:

Patient educationCBTAerobic exerciseMultidisciplinary therapy
Amitriptyline (25/50 mg)     NNT 3,54 (95% CI 2.74, 5.01)Cyclobenzaprine (10/30 mg)

Moderate evidence:
Moderate evidence:

Strength trainingAcupunctureHypnotherapyBiofeedbackBalneotherapy
SNRIs:     Milnacipran (100 mg)         NNT 19 (95% CI 7.4, 20.5)         NNH 7.6 (95% CI 6.2, 9.9)    Duloxetine (60/120 mg)         NNT 7.2 (95% CI 5.2, 11.4)        NNH 14.9 (95% CI 9.1, 41.4)    SSRI:         Fluoxetine (20/80 mg)        Tramadol (200/300 mg)Anticonvulsant:     Pregabalin (300/450 mg)         NNT 8.6 (95% CI 6.4, 12.9)        NNH 7.6 (95%CI 6.3, 9.4)

European League Against Rheumatism (EULAR)
Balneotherapy (grade B)Individually tailored exercise including aerobic and strength training (grade C)Cognitive-behavioral therapy (grade B)Others: relaxation, rehabilitation, physiotherapy, and/or psychological support (grade C)
Tramadol (grade A)Analgesics (paracetamol/acetaminophen, weak opioids) (grade D)Antidepressants (amitriptyline, fluoxetine, duloxetine, milnacipran, moclobemide, pirlindole) (grade A)Tropisetron, pramipexole, pregabalin (grade A)